|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
03.11.25 - 22:06
|
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE (Business Wire)
|
|
|
Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53:
While the ESSENCE study did not achieve statistical significance on its primary endpoint, results indicate positive and encouraging trends favoring therapy at 96 weeks
Sarepta reports that the study was impacted by the COVID-19 pandemic and, when COVID-impacted data is excluded, meaningful treatment effect is seen on the primary endpoint
ESSENCE supported favorable safety profile of AMONDYS 45 and VYONDYS 53
The Company intends to schedule a meeting with FDA to discuss path to a traditional approval based on the positive risk-benefits of the therapies from the results of the ESSENCE study and significant positive multi-year real-world evidence
Net product revenues for the third quarter 2025 totaled $370.0 million, consisting of $238.5M of PMO and $131.5M of ELEVIDYS
Refinancing of a majority portion of 2027 Notes and cost restructuring initiatives strengthened overall finan...
|
|
|
|
|
|
|
27.10.25 - 21:06
|
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results (Business Wire)
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2025 financial results and recent corporate developments.
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medi...
|
|
|
13.10.25 - 14:00
|
Sarepta-Aktie: Zurück zu altem Glanz? (Sharedeals)
|
|
|
Die Aktie von Sarepta Therapeutics steht wieder im Fokus der Biotech-Anleger. Nach einem starken Umsatzwachstum und hohen Erwartungen an neue Gentherapien fragen sich viele, ob das Papier seinen nächsten Kurssprung schaffen kann – oder ob Sicherheitsrisiken die Rallye ausbremsen werden. Mit der Sarepta-Aktie haben SD-Leser gute Erfahrungen gemacht: Unser Trade im Sommer hatte über Nacht […]
The post Sarepta-Aktie: Zurück zu altem Glanz? first appeared on sharedeals.de....
|
|
|
|
|
01.10.25 - 00:03
|
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2025 (the “Grant Date”) that were approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in the third quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 49,805 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date, such that the RSUs granted to each employee will be fully vested on the fourth anniversary of the Grant Date, in each case, subject to each such employee's continued employment with Sarepta on such vesting date.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases tha...
|
|
|
|
|
|
|
03.09.25 - 14:03
|
Pretzel Therapeutics Strengthens Leadership with Appointment of Ashish Dugar, Ph.D., MBA as Chief Development Officer (Business Wire)
|
|
|
- Veteran biotech leader from Dyne, Sarepta, Intra-Cellular, Roche and Pfizer joins Pretzel to accelerate first-in-class bioenergetics pipeline -WALTHAM, Mass.--(BUSINESS WIRE)--#pipeline--Pretzel Therapeutics, a leader in harnessing cellular energetics to develop novel treatments for a range of conditions spanning neurological, muscle, metabolic and rare diseases, today announced the appointment of Ashish Dugar, Ph.D., MBA as Chief Development Officer (CDO). Dr. Dugar joins Pretzel with nearly 25 years of industry experience across clinical development, medical affairs and commercial leadership roles, most recently at Dyne Therapeutics where he oversaw global medical affairs for rare neuromuscular diseases.
“We are thrilled to welcome Ash to Pretzel as our Chief Development Officer overseeing clinical strategy and execution across our growing pipeline from early-stage development through clinical trials and regulatory submission,” said Jay Parrish, Ph.D., Chairman of the Board and Chief Executive Off...
|
|
|
27.08.25 - 21:09
|
Sarepta Therapeutics Aktie fällt 10% - Deutsche Bank sieht FDA-Sicherheitsmeldung als Grund (Aktiencheck)
|
|
|
Frankfurt (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von der Deutschen Bank:
Die Analysten der Deutschen Bank raten die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN: A1J1BH, Ticker-Symbol: AB3A, NASDAQ-Symbol: SRPT) zu verkaufen.
Die Deutsche Bank führe den 10%igen Kursrückgang der Sarepta-Aktie in der vergangenen Woche zumindest teilweise auf einen neuen Eintrag im FDA Adverse Event Reporting System für Elevidys zurück. [mehr]...
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
